Adjuvant T-DM1 Outperforms Trastuzumab in HER2-Positive Early Breast Cancer
February 12th 2025Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease after neoadjuvant therapy.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2-Positive Early Breast Cancer
December 8th 2023After more than 8 years of follow-up, T-DM1 continued to improve invasive disease-free survival and overall survival in patients with HER2-positive early breast cancer that had residual invasive disease.
Adding Ribociclib to Aromatase Inhibitor Treatment Improves iDFS in Early Breast Cancer
December 8th 2023Adjuvant ribociclib plus standard non-steroidal aromatase inhibitors improved invasive disease-free survival in HR-positive, HER2-negative early breast cancer, compared with nonsteroidal aromatase inhibitors alone.
Acalabrutinib Appears to Have Quicker Time to Next Therapy Than Ibrutinib in Patients With CLL
December 12th 2022Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.
Lenvatinib/Pembrolizumab Benefit Maintained in Advanced Endometrial Cancer
September 11th 2022After extended follow-up, continued benefit was seen with the combination of lenvatinib and pembrolizumab in patients with advanced endometrial cancer who previously received platinum chemotherapy, updated efficacy and safety findings from the phase 3 Study 309/KEYNOTE-775 trial showed.
Daratumumab Added to RVd Achieved MRD Negativity, PFS Improvement in Newly Diagnosed Myeloma
June 5th 2022Among patients with newly diagnosed, transplant-eligible myeloma treated in a phase 2 study, induction and consolidation with daratumumab plus the RVd regimen outperformed RVd alone in terms of minimal residual disease and progression-free survival.
Real-World Data Demonstrate Efficacy, Safety With Tivozanib in mRCC
February 19th 2022Tivozanib as first-line treatment showed noninferiority compared with other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma in a real-world setting. This is an attractive option for patients due to tivozanib’s tolerable safety profile.